From pathogenesis to new targets for treating diffuse large B-cell lymphoma

Who could benefit from this research

What this research studies

This project explores why diffuse large B-cell lymphoma (DLBCL) behaves so differently among patients by studying genetic regions outside the protein-coding parts of the genome. Researchers will examine enhancer regions and other regulatory DNA to understand how they contribute to cancer growth and resistance to treatment. The goal is to identify new molecular targets that could lead to more precise and effective therapies for people with DLBCL. If successful, the work could translate into future clinical trials and personalized treatment options. The study is conducted at Columbia University and involves experts in cancer biology and genomics.

Why it matters

Where this research is happening

• Columbia University Health Sciences
  New York, United States Active

Researchers

• Principal investigator: Dalla-Favera, Riccardo — Columbia University Health Sciences
• Study coordinator: Dalla-Favera, Riccardo

Related research

Other NIH-funded projects on the same topics.

• Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma

  A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11403920

• Cardioprotective treatment choices for DLBCL patients at risk of heart damage

  Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11402640

• Translating Genomics to Practice to Overcome Disparities in DLBCL

  A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11401446

• Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma

  A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.

  NIH research University of Chicago · Chicago, United States · NIH-11353865

• Lowering c-Myc to treat aggressive large B‑cell lymphoma

  This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11321531

• EBV-related lymphoma in people with immune deficiency: understanding what drives the disease

  A doctor-scientist team will study a type of blood cancer linked to the Epstein-Barr virus in people with immune system problems to learn what makes it worse and how we can diagnose and treat it better.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11300775

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.